For secondary prevention in higher risk patients who are willing to intensify treatment, we suggest adding ezetimibe to either moderate- or high-dose statins for reducing non-fatal cardiovascular events following a discussion of the risks, additional benefits, and an exploration of the patient s values and preferences. Weak for [75,76,80,81] Weak for Reviewed, New- replaced 14. For secondary prevention in higher risk patients who are willing to intensify treatment, we suggest offering a PCSK9 inhibitor in addition to a maximally tolerated statin dose with ezetimibe for reducing non-fatal cardiovascular events following a discussion of their uncertain long-term safety, additional benefits, and an exploration of the patient s values and preferences. Strong against [68,70,79,82-85,88,89] Additional references: Weak for Reviewed, New- replaced Recommendation 2014 Strength of Recommendation Evidence 2020 Strength of Recommendation Recommendation Category 15. For primary or secondary prevention, we recommend against using niacin (i.e., supplements or prescriptions). Strong against [90-92] Additional references: Strong against Reviewed, New- replaced 16. For primary or secondary prevention, we suggest against adding fibrates to statins. Strong against [90,94-97] Additional references: Weak against Reviewed, New- replaced 17. There is insufficient evidence to recommend for or against using bempedoic acid with or without statins for either primary or secondary prevention. Not applicable [98] Neither for nor against Reviewed, New- added 18. For primary prevention, there is insufficient evidence to recommend for or against icosapent ethyl in patients on statin therapy with persistently elevated fasting triglycerides. Not applicable [99] Neither for nor against Reviewed, New- added 19. For secondary prevention, we suggest offering icosapent ethyl in patients on statin therapy with persistently elevated fasting triglycerides >150 mg/dL to reduce cardiovascular morbidity and mortality. Not applicable [99] Weak for Reviewed, New- added 20. 